Cargando…

The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis

BACKGROUND: Family with sequence similarity 83 member H antisense RNA 1 (FAM83H-AS1) is a novel long non-coding RNA. Increasing studies have reported that FAM83H-AS1 is abnormally expressed in a variety of tumors and is associated with poor outcome. However, the clinical prognostic significance of l...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Qin, Wang, Jie, Zhong, Pingyong, Mou, Tinggang, Hua, Hao, Liu, Pan, Xie, Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059312/
https://www.ncbi.nlm.nih.gov/pubmed/32165862
http://dx.doi.org/10.1186/s12935-020-1148-8
_version_ 1783504024102764544
author Yang, Qin
Wang, Jie
Zhong, Pingyong
Mou, Tinggang
Hua, Hao
Liu, Pan
Xie, Fei
author_facet Yang, Qin
Wang, Jie
Zhong, Pingyong
Mou, Tinggang
Hua, Hao
Liu, Pan
Xie, Fei
author_sort Yang, Qin
collection PubMed
description BACKGROUND: Family with sequence similarity 83 member H antisense RNA 1 (FAM83H-AS1) is a novel long non-coding RNA. Increasing studies have reported that FAM83H-AS1 is abnormally expressed in a variety of tumors and is associated with poor outcome. However, the clinical prognostic significance of lncRNA FAM83H-AS1 in tumors is not completely known. METHODS: In this meta-analysis, literature was collected up until February 5, 2020 through multifarious retrieval strategies by searching through electronic databases of PubMed, Cochrane Library, EMBASE, Medline, Web of Science, CNKI, Weipu, and Wanfang. A total of 14 studies that met the inclusion criteria with relevant clinical data and prognostic information were included in the meta-analysis. RESULTS: The combined results revealed that high expression of FAM83H-AS1 was associated with poor overall survival (OS) (HR = 1.63, 95% CI 1.24–2.14, P = 0.0004) in a variety of cancers. Additionally, upregulated FAM83H-AS1 expression was significantly correlated with tumor TNM stage (III/IV vs. I/II, OR = 2.40, 95% CI 1.36–4.23, P = 0.003) and lymph node metastasis (positive vs. negative, OR = 1.70, 95% CI 1.14–2.52, P = 0.008) in patients with cancer. CONCLUSIONS: Our results of this meta-analysis indicated that elevated FAM83H-AS1 expression could predict poor prognosis in patients with cancer and suggested that FAM83H-AS1 might serve as a novel biomarker for cancer.
format Online
Article
Text
id pubmed-7059312
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70593122020-03-12 The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis Yang, Qin Wang, Jie Zhong, Pingyong Mou, Tinggang Hua, Hao Liu, Pan Xie, Fei Cancer Cell Int Review BACKGROUND: Family with sequence similarity 83 member H antisense RNA 1 (FAM83H-AS1) is a novel long non-coding RNA. Increasing studies have reported that FAM83H-AS1 is abnormally expressed in a variety of tumors and is associated with poor outcome. However, the clinical prognostic significance of lncRNA FAM83H-AS1 in tumors is not completely known. METHODS: In this meta-analysis, literature was collected up until February 5, 2020 through multifarious retrieval strategies by searching through electronic databases of PubMed, Cochrane Library, EMBASE, Medline, Web of Science, CNKI, Weipu, and Wanfang. A total of 14 studies that met the inclusion criteria with relevant clinical data and prognostic information were included in the meta-analysis. RESULTS: The combined results revealed that high expression of FAM83H-AS1 was associated with poor overall survival (OS) (HR = 1.63, 95% CI 1.24–2.14, P = 0.0004) in a variety of cancers. Additionally, upregulated FAM83H-AS1 expression was significantly correlated with tumor TNM stage (III/IV vs. I/II, OR = 2.40, 95% CI 1.36–4.23, P = 0.003) and lymph node metastasis (positive vs. negative, OR = 1.70, 95% CI 1.14–2.52, P = 0.008) in patients with cancer. CONCLUSIONS: Our results of this meta-analysis indicated that elevated FAM83H-AS1 expression could predict poor prognosis in patients with cancer and suggested that FAM83H-AS1 might serve as a novel biomarker for cancer. BioMed Central 2020-03-06 /pmc/articles/PMC7059312/ /pubmed/32165862 http://dx.doi.org/10.1186/s12935-020-1148-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Yang, Qin
Wang, Jie
Zhong, Pingyong
Mou, Tinggang
Hua, Hao
Liu, Pan
Xie, Fei
The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis
title The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis
title_full The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis
title_fullStr The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis
title_full_unstemmed The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis
title_short The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis
title_sort clinical prognostic value of lncrna fam83h-as1 in cancer patients: a meta-analysis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059312/
https://www.ncbi.nlm.nih.gov/pubmed/32165862
http://dx.doi.org/10.1186/s12935-020-1148-8
work_keys_str_mv AT yangqin theclinicalprognosticvalueoflncrnafam83has1incancerpatientsametaanalysis
AT wangjie theclinicalprognosticvalueoflncrnafam83has1incancerpatientsametaanalysis
AT zhongpingyong theclinicalprognosticvalueoflncrnafam83has1incancerpatientsametaanalysis
AT moutinggang theclinicalprognosticvalueoflncrnafam83has1incancerpatientsametaanalysis
AT huahao theclinicalprognosticvalueoflncrnafam83has1incancerpatientsametaanalysis
AT liupan theclinicalprognosticvalueoflncrnafam83has1incancerpatientsametaanalysis
AT xiefei theclinicalprognosticvalueoflncrnafam83has1incancerpatientsametaanalysis
AT yangqin clinicalprognosticvalueoflncrnafam83has1incancerpatientsametaanalysis
AT wangjie clinicalprognosticvalueoflncrnafam83has1incancerpatientsametaanalysis
AT zhongpingyong clinicalprognosticvalueoflncrnafam83has1incancerpatientsametaanalysis
AT moutinggang clinicalprognosticvalueoflncrnafam83has1incancerpatientsametaanalysis
AT huahao clinicalprognosticvalueoflncrnafam83has1incancerpatientsametaanalysis
AT liupan clinicalprognosticvalueoflncrnafam83has1incancerpatientsametaanalysis
AT xiefei clinicalprognosticvalueoflncrnafam83has1incancerpatientsametaanalysis